Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill may help diabetics fast safely during ramadan

NCT ID NCT07613307

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 3 times

Summary

This study tests a once-daily pill called orforglipron in adults with type 2 diabetes who plan to fast during Ramadan. The goal is to see if the drug helps control blood sugar and weight without causing harm. About 130 participants will take the pill for up to 48 weeks, with clinic and virtual visits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a clinical diagnosis of T2D based on the World Health Organization (WHO) classification or other locally applicable diagnostic standards. * Have an HbA1c value of at least 7.0% (53 millimoles per mole (mmol/mol)) to less than 9.5% (91 mmol/mol) at screening. * Intend to be compliant with the fast during the Ramadan period. * Have had stable body weight self-reported change of 5 kilograms (kg) or lower during the 90 days prior to screening. * Have body mass index (BMI) of 25 kilograms per meter square (kg/m2) or higher at screening. Exclusion Criteria: * Have any form of diabetes other than T2D, including type 1 diabetes (T1D), gestational diabetes, latent autoimmune diabetes, maturity-onset diabetes of the young, and medication-induced diabetes * Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. * Have a history of chronic or acute pancreatitis any time prior to screening * Have evidence of a significant, uncontrolled endocrine abnormality, for example, thyrotoxic or adrenal crises, in the opinion of the investigator * Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years. * Have a history of cholecystectomy (surgically removed gallbladder) * Have New York Heart Association Functional Classification IV congestive heart-failure.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Behavior are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Behavior diabetes mellitus endocrine system disorder Fasting Feeding Behavior glucose metabolism disease metabolic disease Nutritional and Metabolic Diseases type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Behavior Diabetes melletus Diabetes mellitus type 2 Endocrine system diseases Fasting Feeding behavior Glucagon-like peptide receptors Glucagon-like peptide-1 receptor Glucose metabolism disorders Membrane proteins Metabolic disorders Nutritional and metabolic diseases Proteins Receptors, cell surface Receptors, G-protein-coupled Receptors, peptide

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    40 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aliwal Shoal Medical Centre

    RECRUITING

    eMkhomazi, 4170, South Africa

  • Apollo Multispeciality Hospitals limited

    RECRUITING

    Kolkata, 700054, India

  • Be Part Research (PTY) LTD

    RECRUITING

    Paarl, 7626, South Africa

  • Brij Medical Centre Pvt. Ltd.

    RECRUITING

    Kanpur, 208020, India

  • Burjeel Medical City

    NOT_YET_RECRUITING

    Abu Dhabi, 00000, United Arab Emirates

  • Diabetes Clinic

    RECRUITING

    Nellore, 524001, India

  • Dr JM Engelbrecht Trial Site

    RECRUITING

    Somerset West, 7130, South Africa

  • Dr. Soliman Fakeeh Hospital

    RECRUITING

    Jeddah, 23331, Saudi Arabia

  • Dr. Soliman Fakeeh Hospital

    NOT_YET_RECRUITING

    Riyadh, 11564, Saudi Arabia

  • Drs H & V Makan Centre for Diabetes

    RECRUITING

    Lenasia, 1827, South Africa

  • Dubai Hospital

    NOT_YET_RECRUITING

    Dubai, 7272, United Arab Emirates

  • Emirates Hospital Dubai

    NOT_YET_RECRUITING

    Dubai, 0000, United Arab Emirates

  • Emmed Research

    RECRUITING

    Pretoria, 0002, South Africa

  • Fola Health

    NOT_YET_RECRUITING

    Johannesburg, 2091, South Africa

  • Imam Abdulrahman Bin Faisal University

    RECRUITING

    Dammam, 34212, Saudi Arabia

  • JOSHA Research

    RECRUITING

    Bloemfontein, 9301, South Africa

  • KGN Diabetes and Endocrinology Centre

    RECRUITING

    Mumbai, 400008, India

  • King Abdulaziz University Hospital

    RECRUITING

    Jeddah, 22254, Saudi Arabia

  • King Abdulaziz University for Health Sciences Ministry of National Guard Health Affairs

    NOT_YET_RECRUITING

    Al-Ahsa, 31982, Saudi Arabia

  • King Fahad Armed Forces Hospital Jeddah

    NOT_YET_RECRUITING

    Jeddah, 23311, Saudi Arabia

  • King Fahad Specialist Hospital

    RECRUITING

    Dammam, 32253, Saudi Arabia

  • King Saud University Medical City

    RECRUITING

    Riyadh, 11472, Saudi Arabia

  • Mysore Medical College and Research Institute

    RECRUITING

    Mysore, 570001, India

  • NMC Abu Dhabi

    RECRUITING

    Abu Dhabi, 6222, United Arab Emirates

  • NMC Royal hospital

    NOT_YET_RECRUITING

    Abu Dhabi, 00000, United Arab Emirates

  • National Guard Health Affairs: King Abdulaziz Medical City

    NOT_YET_RECRUITING

    Jeddah, 21423, Saudi Arabia

  • Osepdale Fatebenefratelli e Oftalmico

    NOT_YET_RECRUITING

    Riyadh, 12231, Saudi Arabia

  • Osmania General Hospital

    RECRUITING

    Hyderabad, 500012, India

  • Sarojini Naidu Medical College

    RECRUITING

    Agra, 282003, India

  • Sheikh Khalifa Medical City

    RECRUITING

    Abu Dhabi, 0000, United Arab Emirates

  • Supe Heart & Diabetes Hospital & Research Centre

    RECRUITING

    Nashik, 422002, India

  • Synergy Biomed Research Institute (SBRI)

    RECRUITING

    East London, 5201, South Africa

  • Synopsis Research

    RECRUITING

    Cape Town, 7708, South Africa

  • TASK Central

    RECRUITING

    Cape Town, 7530, South Africa

  • TREAD Research

    RECRUITING

    Cape Town, 7500, South Africa

  • Tawam Hospital

    RECRUITING

    Al Ain City, 15258, United Arab Emirates

  • Tiervlei Trial Centre

    RECRUITING

    Cape Town, 7530, South Africa

  • Trident Clinical

    RECRUITING

    Kimberley, 8301, South Africa

  • Ubuntu Clinical Research Krugersdorp

    RECRUITING

    Krugersdorp, 1739, South Africa

  • Visakha Institute of Medical Sciences

    RECRUITING

    Visakhapatna, 530040, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.